(Total Views: 322)
Posted On: 03/10/2018 12:31:21 PM
Post# of 72444
Plenty of reason to not do a Brilacidin deal now. If Prurisol does great and we get an offer on it ($100M, $500M, $1B, $10B...pick your number) we would have funding to begin all the trials we like for Brilacidin.
IPIX with the following will be able to negotiate a significantly better deal on the Brilacidin platform (or buyout):
$300M in the bank
B ABSSSI Phase 3 in progress and paid
B OM Phase 3 in progress and paid
B UP Phase 2b in progress and paid
Alternatively, if Prurisol puts up some killer numbers (40%PASI75@300mg) it might be worth doing the quick B deal and retaining much larger ownership of an oral psoriasis drug that will generate tens of billions over it's patent life.
All that said, I agree with you and think the odds of a total takeout this year are are as high as any partnership. Looking for $8-30/share depending on how Prurisol does and how pleased BP actually is with the K 2a data.
Go IPIX!
IPIX with the following will be able to negotiate a significantly better deal on the Brilacidin platform (or buyout):
$300M in the bank
B ABSSSI Phase 3 in progress and paid
B OM Phase 3 in progress and paid
B UP Phase 2b in progress and paid
Alternatively, if Prurisol puts up some killer numbers (40%PASI75@300mg) it might be worth doing the quick B deal and retaining much larger ownership of an oral psoriasis drug that will generate tens of billions over it's patent life.
All that said, I agree with you and think the odds of a total takeout this year are are as high as any partnership. Looking for $8-30/share depending on how Prurisol does and how pleased BP actually is with the K 2a data.
Go IPIX!
(1)
(0)
All my posts are my own personal opinion and speculation. They should not be used as the basis for any investment decision. No, I am not Scottsmith.
